Overview

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel-group, Phase 3 study to evaluate the efficacy of the administration of phenobarbital sodium injection in neonates who have suffered from electrographic or electroclinical seizure. As neonatal seizures can have long-term adverse effects, including death, placebo-controlled studies are not appropriate for this population. This study is designed to show intravenous phenobarbital is effective at preventing subsequent seizures by demonstrating greater efficacy at a higher dose compared to a lower dose.
Phase:
Phase 3
Details
Lead Sponsor:
NEMA Research, Inc.
Collaborator:
Hikma Pharmaceuticals USA Inc.
Treatments:
Phenobarbital